DrugPatentWatch Database Preview
Investigational Drug Information for AG-120
Email this page to a colleague
What is the development status for investigational drug AG-120?
AG-120 is an investigational drug.
There have been 23 clinical trials for AG-120.
The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2017.
The most common disease conditions in clinical trials are Leukemia, Myeloid, Acute, Leukemia, Myeloid, and Leukemia. The leading clinical trial sponsors are Agios Pharmaceuticals, Inc., National Cancer Institute (NCI), and Institut de Recherches Internationales Servier.
There are twenty US patents protecting this investigational drug and two hundred and forty-one international patents.
Summary for AG-120
| US Patents | 20 |
| International Patents | 241 |
| US Patent Applications | 113 |
| WIPO Patent Applications | 114 |
| Japanese Patent Applications | 21 |
| Clinical Trial Progress | Phase 3 (2017-01-01) |
| Vendors | 46 |
Recent Clinical Trials for AG-120
| Title | Sponsor | Phase |
|---|---|---|
| Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission | National Cancer Institute (NCI) | Phase 1 |
| Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission | M.D. Anderson Cancer Center | Phase 1 |
| Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation | National Cancer Institute (NCI) | Phase 1 |
Clinical Trial Summary for AG-120
Top disease conditions for AG-120
Top clinical trial sponsors for AG-120
US Patents for AG-120
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| AG-120 | ⤷ Sign up for a Free Trial | Methods of treatment of malignancies | Celgene Corporation (Summit, NJ) Agios Pharmaceuticals, Inc. (Cambridge, MA) | ⤷ Sign up for a Free Trial |
| AG-120 | ⤷ Sign up for a Free Trial | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Sign up for a Free Trial |
| AG-120 | ⤷ Sign up for a Free Trial | Methods of treatment of malignancies | Agios Pharmaceuticals, Inc. (Cambridge, MA) | ⤷ Sign up for a Free Trial |
| AG-120 | ⤷ Sign up for a Free Trial | Oral drug dosage forms having desired drug release profiles and uses thereof | Triastek, Inc. (Nanjing, CN) | ⤷ Sign up for a Free Trial |
| AG-120 | ⤷ Sign up for a Free Trial | Compartmented pharmaceutical dosage forms | Triastek, Inc. (Nanjing, CN) | ⤷ Sign up for a Free Trial |
| AG-120 | ⤷ Sign up for a Free Trial | Pharmaceutical compositions of therapeutically active compounds | Agios Pharmaceuticals, Inc. (Cambridge, MA) | ⤷ Sign up for a Free Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for AG-120
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| AG-120 | Australia | AU2016393869 | 2036-02-26 | ⤷ Sign up for a Free Trial |
| AG-120 | Australia | AU2016393870 | 2036-02-26 | ⤷ Sign up for a Free Trial |
| AG-120 | Canada | CA3015753 | 2036-02-26 | ⤷ Sign up for a Free Trial |
| AG-120 | Canada | CA3015757 | 2036-02-26 | ⤷ Sign up for a Free Trial |
| AG-120 | China | CN109069410 | 2036-02-26 | ⤷ Sign up for a Free Trial |
| AG-120 | European Patent Office | EP3419593 | 2036-02-26 | ⤷ Sign up for a Free Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
